skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Pls comment on the potential of PSNL for its business. Thank you.
Read Answer Asked by Paul on November 25, 2020
Q: Back in May I asked a question about DXCM. It was in the low $400's then and it has since fallen to the low $300's. Do you know the reason for the decline and what do you think of it now? How "expensive" is it now/would you buy? (I never ended up getting any and am thinking of stepping in now)
Read Answer Asked by Max on November 24, 2020
Q: Hello 5i,
I have two questions pertaining to the spin-out:
1. Would I be correct in assuming that if held in an RRSP, there would be NO tax implications at all?
2. When typing in VTRS, I see a second option showing up: VTRSV. What, if any, is the difference? My broker recorded the transaction as VTRS and so that is what I use.
Many thanks, as always!!
Stay safe and well!!
Cheers,
Mike
Read Answer Asked by Mike on November 23, 2020
Q: Hi 5I team.
My question is about healthcare and diversification in the space. I have been attempting to keep my position around the 16% portfolio weighting and currently hold ABBV, AMD, AMGN(4.8%), LLY(3%), PFE, MRNA, and WELL positions. Although I do not want to abandon the PFE/MRNA freight trains, I am looking at adding/shifting to what may be a longer term/higher dividend return avenue with the use of GILD(attractive entry and solid div), CRISPR(awaiting a pull back to $90 if it comes), and even MDT(under $103 if it comes)

How do you feel about this strategy and the switch out of AMGN/LLY to GILD/MDT?

Thank you

Peter
Read Answer Asked by Peter on November 23, 2020
Q: I have been holding BIIB for a couple of years on hopes (I know, that is not an investment strategy) that their alzheimer drug would be approved. It has come close a few times and the stock has reacted very favourably only to fall short of approval and fall back in price. Do you believe that the recent setback will make BIIB dead money for the foreseeable future and its best to move on or is it too cheap and compelling a story to sell now? If BIIB was part of your US Growth portfolio would you keep it or sell in favour of a better growth stock. If your decision would be to sell, what would be the top 2 names for replacement with no regard to sector.

Thanks
Scott
Read Answer Asked by Scott on November 19, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!